Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications
Clinical and Experimental Immunology · 05.07.2023 · 213 (1) · 87-101
DOI: 10.1093/cei/uxad033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 07.03.2023. Verfasst von Isa Seida und 8 weiteren Autor:innen. Beteiligte Einrichtung: International School of Medicine, Istanbul Medipol University, Istanbul, Turkey. Hauptthemen laut MEDLINE: COVID-19, Autoimmune Diseases, Vaccines. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Adjuvants, as the name indicates, are adjoined material aimed to assist in functioning as when added to vaccines they are meant to boost the effect and strongly stimulate the immune system. The response of the immune system can be unpredictable, and the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) was developed to address possible adverse reactions of an autoimmune and inflammatory type that may be caused by adjuvants. While ASIA, as a syndrome, was coined and defined in 2011; reports describing patients with vague and nonspecific clinical symptoms following vaccinations appeared much earlier. In other words, ASIA came to define, arrange, and unite the variety of symptoms, related to autoimmunity, caused not by the vaccine itself, rather by the adjuvant part of the vaccine such as aluminum, among others. Accordingly, the introduction of ASIA enabled better understanding, proper diagnosis, and early treatment of the disorder. Furthermore, ASIA was shown to be associated with almost all body systems and various rheumatic and autoimmune diseases such as systemic lupus erythematosus, antiphospholipid syndrome, and systemic sclerosis. In addition, the correlation between COVID-19 and ASIA was noticed during the pandemic. In this review, we summarized the reported effects of adjuvants and medical literature before and after ASIA was defined, the several ways ASIA can manifest and impact different systems of the body, and the incidences of ASIA during the COVID-19 pandemic. It is important to clarify, that vaccines are among, if not the, most effective means of fighting infectious diseases however, we believe that vaccines manufacturing is not above criticism, particularly when it comes to added substances possessing a risk of side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International School of Medicine, Istanbul Medipol University, Istanbul, Turkey.
ORCID-Profile: Abdulkarim Alwani, Naim Mahroum
Zitieren
APA
Seida, I., Alrais, M., Seida, R., Alwani, A., Kiyak, Z., Elsalti, A., Nil Esirgun, S., Abali, T., & Mahroum, N. (2023). Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications. Clinical and Experimental Immunology, 213(1), 87-101. https://doi.org/10.1093/cei/uxad033
Vancouver
Seida I, Alrais M, Seida R, Alwani A, Kiyak Z, Elsalti A, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications. Clinical and Experimental Immunology. 2023;213(1):87-101. doi:10.1093/cei/uxad033
BibTeX
@article{Seida2023,
author = {Seida, Isa and Alrais, Mahmoud and Seida, Ravend and Alwani, Abdulkarim and Kiyak, Zeynep and Elsalti, Abdulrahman and Nil Esirgun, Sevval and Abali, Tunahan and Mahroum, Naim},
title = {Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications},
journal = {Clinical and Experimental Immunology},
year = {2023},
volume = {213},
number = {1},
pages = {87--101},
doi = {10.1093/cei/uxad033}
}
EUVIMED